[go: up one dir, main page]

EA200300046A1 - QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION - Google Patents

QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION

Info

Publication number
EA200300046A1
EA200300046A1 EA200300046A EA200300046A EA200300046A1 EA 200300046 A1 EA200300046 A1 EA 200300046A1 EA 200300046 A EA200300046 A EA 200300046A EA 200300046 A EA200300046 A EA 200300046A EA 200300046 A1 EA200300046 A1 EA 200300046A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
stomach
volume
retaining
therapeutic agents
Prior art date
Application number
EA200300046A
Other languages
Russian (ru)
Inventor
Моше Флэшнер-Барек
Е. Ицхак Лернер
Веред Розенбергер
Мазал Дахан
Израэл Маков
Original Assignee
Тева Фармасьютикал Индастриес Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриес Лтд. filed Critical Тева Фармасьютикал Индастриес Лтд.
Publication of EA200300046A1 publication Critical patent/EA200300046A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Данное изобретение относится к фармацевтической композиции, которую используют в лекарственной форме для орального введения больному. Композиция увеличивается в объеме при контакте с желудочной жидкостью и стимулирует задерживание лекарственной формы в желудке больного в течение продолжительного периода времени. Кроме того, данное изобретение относится к фармацевтическим лекарственным формам, содержащим активный ингредиент и фармацевтическую композицию. Формы предназначены для немедленного или контролируемого выделения активного ингредиента. Лекарственные формы можно преимущественно использовать при лечении болезни Паркинсона с помощью леводопа и лечения расстройства, связанного с повышенной активностью или недостатком внимания, с помощью метилфенидата.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention relates to a pharmaceutical composition, which is used in a dosage form for oral administration to a patient. The composition increases in volume upon contact with gastric fluid and stimulates the retention of the dosage form in the patient's stomach for an extended period of time. In addition, this invention relates to pharmaceutical dosage forms containing the active ingredient and the pharmaceutical composition. Forms are intended for immediate or controlled release of the active ingredient. Dosage forms can be advantageously used in the treatment of Parkinson's disease with levodopa and the treatment of disorders associated with increased activity or lack of attention with methylphenidate. The international application was published together with an international search report.

EA200300046A 2000-06-23 2001-06-22 QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION EA200300046A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US21711000P 2000-07-10 2000-07-10
US22321200P 2000-08-04 2000-08-04
PCT/US2001/020134 WO2002000213A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Publications (1)

Publication Number Publication Date
EA200300046A1 true EA200300046A1 (en) 2003-10-30

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300046A EA200300046A1 (en) 2000-06-23 2001-06-22 QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION

Country Status (11)

Country Link
EP (1) EP1305021A4 (en)
JP (1) JP2004501190A (en)
KR (1) KR20030013460A (en)
AU (2) AU2001268722B8 (en)
CA (1) CA2412490A1 (en)
CZ (1) CZ2003199A3 (en)
EA (1) EA200300046A1 (en)
HU (1) HUP0301465A3 (en)
IL (1) IL153497A0 (en)
MX (1) MXPA02012793A (en)
WO (1) WO2002000213A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
JP2005501097A (en) * 2001-08-16 2005-01-13 ザ ステイト オブ オレゴン アクティング バイ アンド スルー ザ ステイト ボード オブ ハイアー エデュケイション、 オン ビハーフ オブ オレゴン ステイト ユニバーシティー Inflatable gastric retention device
BE1015608A6 (en) 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
EP1615632B1 (en) * 2003-04-17 2006-12-06 Jallal Messadek Floating oral formulations for controlled release of betaine
EP1675651A1 (en) * 2003-10-20 2006-07-05 Teva Pharmaceutical Industries Limited Composition and dosage form for sustained effect of levodopa
JP2005132803A (en) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd Gastric retention solids
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (en) * 2004-08-19 2006-10-20 Sanofi Synthelabo PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING ALFUZOSIN
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
WO2006113978A2 (en) 2005-04-27 2006-11-02 Jallal Messadek Insulins combinations
NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
RU2484815C2 (en) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Continuous 24-hour introduction of levodopa/carbidopa into intestine
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
AR062659A1 (en) * 2006-09-08 2008-11-26 Drug Tech Corp COMPOSITION OF LEVODOPA SUSTAINED RELEASE AND METHOD FOR USE
EP2066303B1 (en) * 2006-09-26 2016-05-04 Plensat, LLC System for treatment of eating disorders
CA2673485A1 (en) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
KR20080076382A (en) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 Controlled-Release Formulation of Cilostazol and Method for Preparing the Same
DE102007026037A1 (en) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentive system with alginate body
AU2008282900B2 (en) * 2007-07-27 2014-05-22 Depomed, Inc. Pulsatile gastric retentive dosage forms
MX337213B (en) 2008-06-30 2016-02-17 Tocagen Inc Formulations of 5-fluorocytosine and uses thereof.
JP2012500221A (en) * 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Gastric retentive pharmaceutical composition for treatment and prevention of CNS disorders
US8465768B2 (en) * 2008-11-07 2013-06-18 Samyang Biopharmaceuticals Corporation Pharmaceutical compositions for release control of methylphenidate
WO2012093974A1 (en) * 2011-01-06 2012-07-12 Mahmut Bilgic Improved bisphosphonate formulations
CN103385871B (en) * 2012-05-07 2017-06-23 新疆医科大学 Benserazide micro-capsule floating tablet
CN104334123B (en) 2012-06-07 2019-02-12 意比图密医疗有限公司 expansion device
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
JP6204141B2 (en) * 2013-04-22 2017-09-27 テイカ製薬株式会社 Oral rapidly disintegrating composition for solid preparation
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CA2926082C (en) 2013-10-07 2022-06-14 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
BR112016012615B1 (en) 2013-12-05 2023-02-07 Epitomee Medical Ltd SYSTEMS, AND KIT
CA2977540C (en) * 2015-02-27 2023-10-03 Cingulate Therapeutics LLC Tripulse release stimulant formulations
JP6823539B2 (en) * 2017-05-26 2021-02-03 株式会社ファンケル Gastric retention tablets
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
CN110996922A (en) 2017-06-16 2020-04-10 卡希夫生物科学有限责任公司 Gastroretentive dosage forms for sustained drug delivery
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US11229606B2 (en) 2018-06-18 2022-01-25 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
EP3628004B1 (en) 2018-06-27 2021-09-22 Amneal Complex Products Research LLC Self-regulating osmotic gastroretentive drug delivery systems
JP7044649B2 (en) * 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
EP3968980A1 (en) * 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2020264092A1 (en) * 2019-06-26 2020-12-30 Celista Pharmaceuticals Llc Atomoxetine hydrochloride extended release compositions and methods of use
WO2021176360A1 (en) * 2020-03-02 2021-09-10 Craft Health Pte Ltd Oral dosage forms for extended drug release
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1282650B1 (en) * 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
HUP0002490A2 (en) * 1997-07-23 2000-12-28 Perio Products Ltd. Tannic acid polymer compositions for the controlled release of medicinal substances, especially in the oral cavity

Also Published As

Publication number Publication date
HUP0301465A3 (en) 2006-07-28
MXPA02012793A (en) 2004-07-30
AU6872201A (en) 2002-01-08
HUP0301465A2 (en) 2004-05-28
EP1305021A4 (en) 2009-09-23
CZ2003199A3 (en) 2003-12-17
KR20030013460A (en) 2003-02-14
CA2412490A1 (en) 2002-01-03
AU2001268722B8 (en) 2005-09-29
AU2001268722B2 (en) 2005-08-11
IL153497A0 (en) 2003-07-06
JP2004501190A (en) 2004-01-15
WO2002000213A1 (en) 2002-01-03
EP1305021A1 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
EA200300046A1 (en) QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION
EA200300045A1 (en) COMPOSITION AND MEDICATION FORM FOR THE DETAINED GASTRIC ALLOCATION OF AENDRONATE AND / OR OTHER BIS-PHOSPHONATES
BR9909903A (en) Maximum effectiveness of substances used to improve health and well-being
BR0009016A (en) Composition of apomorphine and sildenafil
EA200601799A1 (en) HYDRAZIDE-CONTAINING COMPOUNDS - CFTR INHIBITORS AND THEIR APPLICATION
DZ1884A1 (en) Liquid oral formulations of alendronate.
NO20043871L (en) Controlled release drug formulations containing a carrier peptide
DE60100595D1 (en) Improved transdermal therapeutic system for the treatment of Parkinson's disease
DE60100994D1 (en) Transdermal therapeutic system for the achievement of high plasma levels of rotigotine in the therapy of Parkinson's disease
IS7006A (en) Dihydrogen 3-piperidinopropiophenone and medicinal products containing said compounds
MXPA05012810A (en) Memantine oral dosage forms.
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
RU95101385A (en) Products containing g-csf and tnf-binding protein
ATE543491T1 (en) COMBINATION PREPARATION CONTAINING IBUPROFEN AND PARACETAMOL
RU2002122084A (en) COMBINATION OF MEDICINES, INCLUDING MIRTAZAPINE, FOR THE TREATMENT OF DEPRESSION AND RELATED DISORDERS
RU2006139819A (en) APPLICATION OF SYMETICON FOR PATIENTS POSITIONED FOR CONSTIPATION
RU2002124141A (en) APPLICATION OF MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDERS
ATE446309T1 (en) CAPILLARY RESISTANCE IMPROVEMENT PEPTIDE SUBSTANCE, PHARMACEUTICAL COMPOSITION BASED THEREOF AND METHOD FOR USE THEREOF
HUP0301408A2 (en) Methods and compositions using sulodexide for the treatment of diabetic nephropathy
BR0104586A (en) Method for treating neurodegeneration
Streifler et al. Calcitonin for pseudoclaudication in lumbar spinal stenosis
WO2005060939A3 (en) Controlled-release pharmaceutical formulation
MA28036A1 (en) USE OF OXCARBAZEPINE IN THE TREATMENT OF PAIN RELATED TO DIABETIC NEUROPATHY AND IN SLEEP IMPROVEMENT
ATE454397T1 (en) TETRAPEPTIDE REGULATING THE BLOOD SUGAR LEVEL IN DIABETES MELLITUS